Drugs / PSA-NCAM(+) NPC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04812431 | Sep 2021 → Oct 2028 expected | paraplegia, quadriplegia, spinal cord injury | S.Biomedics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSA-NCAM(+) NPC | “Subjects with damage to C4-C7 cords diagnosed as AIS-A are administered with PSA-NCAM(+) NPC.” NCT04812431 ↗ |
| Modality | Cell therapy | “transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line” NCT04812431 ↗ |
| Route | Intrathecal | “Cells are administered through intrathecal injection.” NCT04812431 ↗ |